Korro Bio Gross Profit

The latest gross profit for KRRO is $1.1M as of June 2026. That compares with $4M in the prior-year period — down 72.6% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Korro Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, KRRO's gross profit moved from $4M to $1.1M — a 72.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Korro Bio's operating scale or balance-sheet position.

Against Healthcare companies, KRRO currently prints $1.1M for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Korro Bio's growth, margins, and balance sheet.

A gross profit figure of $1.1M for KRRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting KRRO's gross profit ($1.1M), review year-over-year change from $4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.